Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Bavarian Nordic A/S
  6. News
  7. Summary
    BAVA   DK0015998017

BAVARIAN NORDIC A/S

(BAVA)
  Report
Delayed Nasdaq Copenhagen  -  10:59 2022-11-25 am EST
230.90 DKK   -2.08%
11/24Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
GL
11/24Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
AQ
11/23Global markets live: UBS, Apple, Nordstrom, Autodesk, Vmware...
MS
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Luc Debruyne Appointed as Observer to the Board of Directors of Bavarian Nordic

09/20/2022 | 07:02am EST

COPENHAGEN, Denmark, September 20, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the board of directors has appointed Luc Debruyne as an observer to the board with the intent to nominate him for election to the board at the ordinary general meeting in March 2023, where he following the board’s constitution is expected to assume the chairmanship after Gerard van Odijk, who will step down after having served for 15 years on the board.

Luc Debruyne is former President Global Vaccines at GSK, a role he held for the last six years of his 27-year long tenure with the company, where he was a member of GSK’s Corporate Executive Team. He is currently Professor of Practice at the University of Leuven, Faculty of Medicine, Biomedical Sciences Group and serves as non-executive director of the boards of University Hospitals UZ Leuven and Fund Plus. He is furthermore member of the Institutional Advisory Board at VIB, the Life Sciences Board at Greenlight Biosciences Inc, and is Strategy Advisor to the CEO and Chair of the Portfolio Strategy and Management Board of CEPI. Luc Debruyne is also highly regarded as an active contributor and advisor in the global health arena with a focus on R&D and access.

Gerard van Odijk, chairman of the board said: “I am pleased to welcome Luc on the board and look forward to our collaboration until my departure as chairman next year. Luc’s wealth of industry experience combined with strong leadership, global health experience and a proven track record of commercial launches will be a significant contribution to the board and to Bavarian Nordic in our continued endeavor to create one of the largest pure play vaccine companies.”

About Bavarian Nordic
Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacturing and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Government of a non-replicating smallpox vaccine, which has been approved by the FDA, also for the protection against monkeypox. The vaccine is also approved in Europe and Canada. Our commercial product portfolio furthermore contains market-leading vaccines against rabies and tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an Ebola vaccine, which is licensed to the Janssen Pharmaceutical Companies of Johnson & Johnson. We are also committed to the development of a next generation COVID-19 vaccine. For more information visit www.bavarian-nordic.com.

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Contacts
Europe: Rolf Sass Sørensen, Vice President Investor Relations, Tel: +45 61 77 47 43
US: Graham Morrell, Paddock Circle Advisors, graham@paddockcircle.com, Tel: +1 781 686 9600

Company Announcement no. 37 / 2022

Attachment


All news about BAVARIAN NORDIC A/S
11/24Report of transactions of shares and related securities of Bavarian Nordic by persons h..
GL
11/24Report of transactions of shares and related securities of Bavarian Nordic by persons h..
AQ
11/23Global markets live: UBS, Apple, Nordstrom, Autodesk, Vmware...
MS
11/23Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise
GL
11/23Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise
GL
11/22Bavarian Nordic's Monkeypox Vaccine Shows 78% Efficacy In New UK Analysis
MT
11/22Britain says monkeypox shot offers strong 78% protection
RE
11/18Vaccines and drugs in the pipeline for RSV
RE
11/17Bavarian Nordic Wins New Supply Contract for Monkeypox Jab With EU Pandemic Response Ag..
MT
11/17EU secures up to 2 million monkeypox vaccine doses from Bavarian Nordic
RE
More news
Analyst Recommendations on BAVARIAN NORDIC A/S
More recommendations
Financials
Sales 2022 3 092 M 432 M 432 M
Net income 2022 -606 M -84,8 M -84,8 M
Net cash 2022 1 759 M 246 M 246 M
P/E ratio 2022 -26,9x
Yield 2022 -
Capitalization 16 299 M 2 278 M 2 278 M
EV / Sales 2022 4,70x
EV / Sales 2023 1,37x
Nbr of Employees 917
Free-Float 99,7%
Chart BAVARIAN NORDIC A/S
Duration : Period :
Bavarian Nordic A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAVARIAN NORDIC A/S
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 230,90 DKK
Average target price 400,57 DKK
Spread / Average Target 73,5%
EPS Revisions
Managers and Directors
Paul Chaplin President & Chief Executive Officer
Henrik Neilsen Juuel Chief Financial Officer & Executive Vice President
Gerardus Wilhelmus van Odijk Chairman
Laurence de Moerlooze Chief Medical Officer & Executive Vice President
Russell Thirsk Chief Operating Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
BAVARIAN NORDIC A/S-14.10%2 278
JOHNSON & JOHNSON3.61%463 391
ELI LILLY AND COMPANY30.95%347 052
ABBVIE INC.17.89%282 189
PFIZER, INC.-16.66%276 231
MERCK & CO., INC.40.27%272 555